Comments
The Competition Commission has given its green light to the multi-layered reorganisation involving Fortis group companies.
Under the deal, Fortis will be carrying out the rejig that involves three entities — Fortis Healthcare Ltd (FHL), Fortis Malar Hospitals Ltd (FMHL) and SRL Ltd (SRL).
In a tweet today, the Competition Commission of India (CCI) said it has approved the “combination involving internal reorganisation of the Fortis group”.
According to the notice submitted to the fair trade regulator, there would be three “inter-linked and inter-dependent” steps under the rejig.
Fortis Malar will be off-loading its healthcare business to Fortis Healthcare as a slump sale on a going concern basis for a certain consideration. Then, Fortis Healthcare will demerge its diagnostics business as well as investment/shareholding in SRL into Fortis Malar, according to the notice.
In the final step, SRL will be amalgamated into Fortis Malar following which the latter’s name will be changed to SRL Ltd.
The composite scheme was cleared by the respective boards of the three companies in August.
Besides, the watchdog has cleared RPG Life Sciences’ acquisition of assets of Sun Pharmaceutical Industries and Sun Pharma Laboratories.
Separately, CCI has approved the transfer of Raghunathpur power plant to the new joint venture between NLC India and Damodar Valley Corporation (DVC).
DVC will be transferring 1,200 MW Raghunathpur power plant in West Bengal to the joint venture. This will be done as a slump sale on a going concern basis.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.